We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+632.23%
AUM
$51.2B
AUM Growth
+$4.14B
(+8.8%)
Cap. Flow
+$445M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
19.89%
Holding
3,234
New
648
Increased
710
Reduced
838
Closed
835
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.99B |
| 2 |
Microsoft
MSFT
|
+$522M |
| 3 |
Advanced Micro Devices
AMD
|
+$511M |
| 4 |
Amazon
AMZN
|
+$318M |
| 5 |
Apple
AAPL
|
+$317M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$402M |
| 2 |
McDonald's
MCD
|
+$375M |
| 3 |
Visa
V
|
+$366M |
| 4 |
Meta Platforms (Facebook)
META
|
+$319M |
| 5 |
Adobe
ADBE
|
+$272M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.58% |
| 2 | Healthcare | 17.11% |
| 3 | Consumer Discretionary | 13.31% |
| 4 | Financials | 8% |
| 5 | Industrials | 6.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKRO
251
DELISTED
Akero Therapeutics
AKRO
| $43.1M | 0.08% |
923,058
-158,667
| -15% | -$7.27M |
|
252
Tenaris
TS
$26.8B
| $43.1M | 0.08% |
1,437,914
+576,909
| +67% | +$16M |
|
|
HCP
253
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $43M | 0.08% |
1,641,653
+1,288,464
| +365% | +$37.8M |
|
254
MakeMyTrip
MMYT
$5.64B
| $42.9M | 0.08% |
1,591,394
+328,388
| +26% | +$8.43M |
|
255
Veeva Systems
VEEV
$37.4B
| $42.8M | 0.08% |
216,356
-99,549
| -32% | -$18.2M |
|
256
Ultragenyx Pharmaceutical
RARE
$2.55B
| $42.7M | 0.08% |
926,637
+21,112
| +2% | +$979K |
|
257
Amylyx Pharmaceuticals
AMLX
$2.54B
| $42.7M | 0.08% |
1,980,180
+840,940
| +74% | +$22.7M |
|
258
Jackson Financial
JXN
$8.8B
| $42.5M | 0.08% |
1,387,307
-14,521
| -1% | -$468K |
|
259
PUT
VanEck Semiconductor ETF
SMH
$73.2B
| $41.9M | 0.08% |
275,100
-77,900
| -22% | -$10.5M |
|
260
Raymond James Financial
RJF
$34B
| $41.8M | 0.08% |
+402,830
| New | +$37.4M |
|
261
W.P. Carey
WPC
$16.4B
| $41.6M | 0.08% |
628,316
+551,704
| +720% | +$38.4M |
|
262
Corebridge Financial
CRBG
$15B
| $41.2M | 0.08% |
2,334,501
+258,049
| +12% | +$4.3M |
|
263
Lincoln Electric
LECO
$15.4B
| $41.2M | 0.08% |
+207,210
| New | +$36.1M |
|
264
Aecom
ACM
$9.75B
| $40.6M | 0.08% |
+479,928
| New | +$39.4M |
|
|
NEWR
265
DELISTED
New Relic, Inc.
NEWR
| $40.6M | 0.08% |
619,686
+184,994
| +43% | +$13.3M |
|
266
Southern Copper
SCCO
$166B
| $40.4M | 0.08% |
608,133
+389,640
| +178% | +$26.6M |
|
|
267
PUT
Adobe
ADBE
$105B
| $40.3M | 0.08% |
82,500
+43,800
| +113% | +$17.6M |
|
268
Principal Financial Group
PFG
$24.3B
| $40M | 0.08% |
527,218
+337,855
| +178% | +$24.4M |
|
269
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $39.7M | 0.08% |
477,700
-186,700
| -28% | -$15.6M |
|
|
ETNB
270
DELISTED
89bio
ETNB
| $39.5M | 0.08% |
2,086,042
+956,571
| +85% | +$16.8M |
|
271
Cummins
CMI
$88.7B
| $39.4M | 0.08% |
160,525
+140,874
| +717% | +$31.9M |
|
272
Costco
COST
$420B
| $39.3M | 0.08% |
73,020
+72,072
| +7,603% | +$36.5M |
|
273
J.M. Smucker
SJM
$12.8B
| $38.9M | 0.08% |
263,289
-15,405
| -6% | -$2.35M |
|
274
Bilibili
BILI
$7.84B
| $38.5M | 0.08% |
2,550,264
+890,690
| +54% | +$16.3M |
|
275
Peabody Energy
BTU
$2.9B
| $38.5M | 0.08% |
1,775,800
-1,001,460
| -36% | -$22.2M |
|
Similar funds
Marshall Wace's Q2 2023 Portfolio in Review
As of Q2 2023, Marshall Wace held 3,234 positions worth $51.2B, up 8.8% from $47.1B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Marshall Wace's Q2 2023 filing shows 648 new, 710 increased, 838 reduced and 835 closed positions. Its largest new stake was iShares Core S&P 500 ETF: 4,713,944 shares worth $2.1B. The largest sale was Gilead Sciences, an estimated $402M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Marshall Wace's largest Q2 2023 buy was iShares Core S&P 500 ETF: 4,713,944 shares worth $2.1B.
- Marshall Wace added most to Microsoft in Q2 2023, an estimated $522M increase.
- Marshall Wace's biggest Q2 2023 reduction was Gilead Sciences, cutting an estimated $402M.
- Marshall Wace fully exited Cloudflare in Q2 2023, selling an estimated $136M.
- Marshall Wace's ten largest holdings make up 20% of its $51.2B portfolio in Q2 2023.
- Marshall Wace opened 648 new positions and closed 835 in Q2 2023.
- Marshall Wace's portfolio value rose 8.8% quarter-over-quarter to $51.2B.
Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.